Metastatic breast cancer
Metastatic breast cancer, also referred to as advanced breast cancer, secondary tumors, secondaries or stage IV breast cancer, is a stage of breast cancer in which malignant cells arising from breast tissue have spread to distant sites beyond the regional lymph nodes. Stage IV is the most advanced stage of breast cancer. Metastatic breast cancer cannot be cured, but it can be treated to enable women to live longer and to lessen symptoms.
Metastasis can occur several years after the primary breast cancer, although it is sometimes diagnosed at the same time as the primary breast cancer or, rarely, before the primary breast cancer has been diagnosed. A 2021 global metanalysis of over 400 studies suggests that between 6% and 22% of women with breast cancer develop metastases. From 6-10% of women have cancer that has already spread beyond the breast at the time of first diagnosis, referred to as de novo stage IV cancer.
Breast cancer metastases can appear anywhere in the body but most often spread to the bones, lungs, liver, and brain, with the most common site being bone. These distant metastases are the cause of most of the deaths due to breast cancer. Metastatic breast cancer cells frequently differ from the preceding primary breast cancer in ways that permit them to metastasize to distant sites, and may have developed resistance to previous types of treatment. However, they are still breast cancer cells, not bone cancer or lung cancer cells, and are treated as such.
Treatment of metastatic breast cancer depends on location of the metastatic tumors and can include chemotherapy, hormonal therapy. immunotherapy, radiation, and surgery. Subtypes of metastatic breast cancer are associated with varying patterns of occurrence, spread and prognosis. To help determine treatment, tumor biopsy samples are tested for biomarkers that affect cell growth. Tumors containing either estrogen receptors (ER) or progesterone receptors (PR) are called hormone receptor-positive (HR+) and can be treated with hormone therapies. Tumors that contain large amounts of the protein human epidermal growth factor receptor 2 (HER2) can be treated with HER2-targeted therapies. Tumors that do not contain ER, PR, or HER2 are called triple-negative tumors. Triple-negative tumors tend to grow more quickly than other breast cancer types.